Urinary piRNA Biomarker Detection for Early Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an ongoing need for sensitive and reliable biomarkers to enable early detection, disease stratification, and risk prediction of Type II Diabetes mellitus (T2DM) to facilitate effective therapeutic interventions and reduce disease progression.
Innovation Solution
Utilizing hsa_piR_020485, a PIWI-interacting RNA isolated from urinary extracellular vesicles, as a biomarker for diagnosing and treating T2DM through non-invasive methods involving urine sample collection, ECV isolation, and quantification of hsa_piR_020485 levels using next-generation sequencing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional diagnostic methods are used for T2DM detection, then the diagnostic process is simple and quick, but the sensitivity and reliability of early detection are insufficient
Solution Approach 1:
The patent uses urinary extracellular vesicles (ECVs) as an intermediary carrier to deliver and protect piRNA biomarkers for detection. The ECVs serve as a natural packaging mechanism that protects the fragile RNA molecules from degradation in urine, enabling reliable detection while maintaining a relatively simple non-invasive urine collection procedure for patients
Solution Approach 2:
The patent replaces traditional mechanical/invasive diagnostic procedures (blood draws, tissue biopsies) with a biochemical detection system based on next-generation sequencing of RNA molecules from urine samples. This substitution maintains high diagnostic accuracy while eliminating the invasiveness and complexity of traditional diagnostic mechanical procedures
2Reliability
If invasive diagnostic procedures are used to obtain biomarkers, then the reliability of biomarker detection is high, but the ease of operation and patient comfort deteriorate
Solution Approach 1:
The patent utilizes the body's natural excretory system to provide the diagnostic sample. Urine is automatically produced and excreted by the body without requiring any invasive procedures, making sample collection trivial for patients while still providing access to valuable biomarkers (piRNAs in ECVs) that reflect pancreatic and metabolic health status
3Measurement precision
If early detection methods with high sensitivity are implemented, then the diagnostic accuracy improves, but the cost and complexity of the detection system increase
Solution Approach 1:
The patent extracts and isolates specific piRNA molecules from the complex mixture of RNA in urinary ECVs using targeted molecular biology techniques. By focusing detection efforts on specific piRNA sequences rather than analyzing all RNA simultaneously, the method achieves high measurement precision while reducing the computational and analytical complexity of the sequencing process
Solution Approach 2:
The patent performs preliminary enrichment and isolation of ECVs from urine, and preliminary extraction of RNA from the ECVs, before applying next-generation sequencing. These preliminary steps concentrate the target biomarkers and remove interfering substances, enabling more precise measurement with reduced sequencing complexity and lower costs
Data Source
AI summary
A method for detecting and treating Type II Diabetes includes the use of hsa_piR_020485, a PIWI-interacting RNA isolated from urinary extracellular vesicles (ECVs), as a biomarker for the diagnosis and treatment of Type 2 diabetes mellitus (T2DM). The method is non-invasive, utilizing the differential expression of hsa_piR_020485 in diabetic versus non-diabetic subjects to identify subjects in need of treatment for T2DM. The method includes obtaining a urine sample from a subject, isolating urinary ECVs from the urine sample, extracting total RNA from the isolated urinary ECVs, quantifying hsa_piR_020485 levels from the total RNA, determining if the hsa_piR_020485 expression level exceeds a threshold, and administering one or more T2DM treatments.